Literature DB >> 27061281

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.

Nicholas Gulati1, Richard D Carvajal2, Michael A Postow3,4, Jedd D Wolchok3, James G Krueger1.   

Abstract

Entities:  

Keywords:  diphencyprone; immunotherapy; melanoma; pembrolizumab

Mesh：

Substances：

Year:  2016        PMID： 27061281      PMCID： PMC4927368          DOI： 10.1111/exd.13030

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN： 0906-6705            Impact factor:   3.960


× No keyword cloud information.
  6 in total

1.  Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.

Authors:  Taku Fujimura; Sadanori Furudate; Aya Kakizaki; Yumi Kambayashi; Takahiro Haga; Akira Hashimoto; Setsuya Aiba
Journal:  J Dermatol       Date:  2015-12-12       Impact factor: 4.005

2.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

3.  Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.

Authors:  Murat Durdu; Deren Özcan; Mete Baba; Deniz Seçkin
Journal:  J Am Acad Dermatol       Date:  2015-02-01       Impact factor: 11.527

Review 4.  Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.

Authors:  Diona L Damian; Robyn P M Saw; John F Thompson
Journal:  J Surg Oncol       Date:  2013-11-19       Impact factor: 3.454

5.  Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights.

Authors:  Nicholas Gulati; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Patricia Gilleaudeau; Mary Sullivan-Whalen; Joel Correa da Rosa; Inna Cueto; Hiroshi Mitsui; James G Krueger
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

6.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
  6 in total
  8 in total

Review 1.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

Authors:  Elizabeth H Byrne; David E Fisher
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

Review 2.  Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata.

Authors:  Kun-Wei Lai; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-22

Review 3.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

Review 4.  Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity.

Authors:  Aleksey Molodtsov; Mary Jo Turk
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

Review 5.  Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.

Authors:  Brendon J Coventry
Journal:  Ther Adv Vaccines Immunother       Date:  2019-08-01

6.  Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.

Authors:  Taku Fujimura; Takanori Hidaka; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Hisayuki Tono; Akira Tsukada; Takahiro Haga; Akira Hashimoto; Ryo Morimoto; Takuhiro Yamaguchi; Tadao Takano; Setsuya Aiba
Journal:  Oncotarget       Date:  2017-04-13

7.  Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.

Authors:  Ivana Lameiras Gibbons; Marina Sonagli; Eduardo Bertolli; Mariana Petaccia de Macedo; Clovis Antonio Lopes Pinto; João Pedreira Duprat Neto
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896

8.  Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.

Authors:  Taku Fujimura; Yota Sato; Kayo Tanita; Yumi Kambayashi; Atsushi Otsuka; Yasuhiro Fujisawa; Koji Yoshino; Shigeto Matsushita; Takeru Funakoshi; Hiroo Hata; Yuki Yamamoto; Hiroshi Uchi; Yumi Nonomura; Ryota Tanaka; Megumi Aoki; Keisuke Imafuku; Hisako Okuhira; Sadanori Furudate; Takanori Hidaka; Setsuya Aiba
Journal:  Oncotarget       Date:  2018-02-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.